IMMX
Immix Biopharma, Inc.
Key Financials
Net Income
$-29438613
↓ 36.2%
Operating Income
$-29956415
↓ 32.1%
Total Assets
$104.8M
↑ 356.9%
Shareholders' Equity
$13.3M
↓ 19.2%
Total Liabilities
$11.0M
↑ 13.9%
Cash & Equivalents
$93.9M
↑ 431.2%
Revenue
$20.0M
0.0%
EPS (Diluted)
$-0.89
↓ 17.1%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 6/5/2026 | View on SEC |
| 8-K | 5/29/2026 | View on SEC |
| 4 | 5/29/2026 | View on SEC |
| 4 | 5/29/2026 | View on SEC |
| 4 | 5/29/2026 | View on SEC |
| 4 | 5/29/2026 | View on SEC |
| 4 | 5/29/2026 | View on SEC |
| 4 | 5/29/2026 | View on SEC |
| 4 | 5/29/2026 | View on SEC |
| 4 | 5/29/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | IMMX |
| Company Name | Immix Biopharma, Inc. |
| CIK | 1873835 |
| Sector | Pharmaceutical Preparations |
| Industry | Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | (888) 958-1084 |